Eurizon Capital SGR S.p.A. Buys New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Eurizon Capital SGR S.p.A. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, HoldingsChannel.com reports. The fund bought 13,565 shares of the biopharmaceutical company’s stock, valued at approximately $10,472,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after purchasing an additional 26,884 shares in the last quarter. Dodge & Cox grew its holdings in shares of Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after purchasing an additional 724,562 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 6.0% in the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock valued at $1,379,329,000 after purchasing an additional 139,647 shares in the last quarter. Capital World Investors grew its holdings in shares of Regeneron Pharmaceuticals by 1.6% in the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock valued at $1,123,609,000 after purchasing an additional 32,348 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after purchasing an additional 408,649 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on REGN. Canaccord Genuity Group cut their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Finally, Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $614.78 on Monday. The firm has a market capitalization of $64.99 billion, a P/E ratio of 14.98, a P/E/G ratio of 1.36 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average price of $719.15 and a 200-day moving average price of $744.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the firm earned $8.22 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron said the World Health Organization recommended its Ebola antibody treatment, Inmazeb, for investigational use in response to the current Bundibugyo ebolavirus outbreak, highlighting continued relevance for an approved infectious-disease asset. Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
• Positive Sentiment: The company expanded its clinical pipeline with a new Phase 2 trial for REGN13335 in pulmonary hypertension, adding another potential growth driver. Regeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335
• Positive Sentiment: Regeneron also announced a new Phase 1 CAR T study in advanced prostate cancer, reinforcing its push into oncology and cell therapy. Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial
• Neutral Sentiment: Brokerage coverage remains supportive, with Regeneron receiving an average “Moderate Buy” recommendation from analysts, which can help cushion sentiment but is not a major catalyst. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Brokerages
• Neutral Sentiment: Recent articles about REGN trading lower since its last earnings report mainly reflect post-earnings drift and analyst estimate checks rather than a fresh company-specific setback. Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: A law firm investor alert announcing an investigation into claims on behalf of Regeneron shareholders may have added legal overhang and contributed to negative sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.